Feb 24, 2021 — VGX-3100 is Inovio's late-stage DNA immunotherapy candidate. It is currently in two Phase III trials (REVEAL 1 and REVEAL 2) with the ...
DOWNLOAD: https://byltly.com/2f73la
DOWNLOAD: https://byltly.com/2f73la
inovio-reveal-1
Aug 7, 2018 — Opened a total of 70 sites across 16 countries and are actively recruiting for REVEAL 1, Inovio's Phase 3 clinical trial for treating cervical .... Mar 3, 2021 — Inovio's REVEAL 1 trial of VGX-3100 to treat high-grade precancerous cervical dysplasia caused by HPV-16/18 meets primary and secondary ... 939c2ea5af
Comentarios